MIRA
INFORM REPORT
|
Report Date : |
06.06.2007 |
IDENTIFICATION DETAILS
|
Name : |
KAHIRA PHARMACEUTICALS & CHEMICAL INDUSTRIES CO SAE |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
1962 |
|
|
|
|
Com. Reg. No.: |
117247,
|
|
|
|
|
Legal Form : |
Societe Anonyme
Egyptienne – SAE (Egyptian Joint Stock Company) |
|
|
|
|
Line of Business : |
Manufacture and export of pharmaceutical and chemical
products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 800,000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name :
KAHIRA
PHARMACEUTICALS & CHEMICAL INDUSTRIES CO SAE
Country of Origin :
Legal Form : Egyptian Joint Stock Company
Registration Date : 1962
Commercial Registration Number :
117247,
Authorised Capital : £E 100,000,000
Issued Capital : £E 53,100,000
Paid up Capital : £E 53,100,000
Total Workforce : 2,500
Line of Business : Manufacture and export of pharmaceutical and chemical products
Financial Condition : Undetermined
Payments : Nothing detrimental uncovered
COMPANY NAME
KAHIRA PHARMACEUTICALS & CHEMICAL INDUSTRIES CO SAE
ADDRESS
Registered & Physical Address
Street :
Area :
PO Box : 793
Town :
Country :
Telephone : (20-2) 2021431
/ 2026931 / 2028596 / 2022783 / 2022744
Facsimile : (20-2) 2025477
Premises
Subject operates
from a large suite of offices that are owned and located in the Suburban
Business Area of Cairo.
Branch Office
(s)
Location Description
·
·
Garden
City
Tel: (20-2)
7956578 / 7956579
·
Tel: (20-3)
5718733
KEY PRINCIPALS
·
Dr. Mohamed Ossama Ziada Chairman
·
Dr. Mohamed Abd El Azim Managing
Director
·
Mohsen El Ayouty Director
·
Dr. Moustafa El Awadi Director
·
Dr. Mohamed Fathallah Director
·
Mohamed Sedik Saber Refaat Director
·
Aref Mohamed Kamal Director
·
Essmat Attia General
Manager
·
Talaat El Nahass Finance
Manager
·
Dr. Farid Diab Sales
Manager
·
Dr. Ahmed Arafa Marketing
Manager
·
Fatma Dawoud Production
Manager
LEGAL FORM &
OWNERS
Date of Establishment : 1962
Legal Form :
Societe Anonyme Egyptienne
– SAE (Egyptian Joint Stock Company)
Commercial Reg. No. : 117247,
Authorised
Capital : £E 100,000,000
Issued Capital : £E
53,100,000
Paid up Capital : £E 53,100,000
Name of Shareholder
(s) Percentage
·
Holding Co for Pharmaceuticals, Chemicals & Medical Appliances
60%
·
Employee Shareholders Association 10%
·
Egyptian
businessmen & private investors 30%
Note to the Legal Form The Egyptian Company Law provides that the capital of a Societe Anonyme Egyptienne - SAE – should not be less than £E 500,000 if shares are offered to the public and £E 250,000 if not. If shares are offered to the public they are freely transferable, if not, transfer may be restricted. Liability of shareholders is limited.
LINE OF BUSINESS
Operations : Engaged in the manufacture and export of
pharmaceutical and chemical products.
Subject
exports more than 30 registered products with licenses from international
companies such as Abbott, Zeneca, MSD, SKF and Searle. Products include human
and veterinary drugs, cosmetics, chemical products and pesticides.
Import Countries
:
Export Countries
:
Subject has a workforce
of approximately 2,500 employees.
FINANCIAL HIGHLIGHTS
Companies
registered in
BANKERS
·
Banque
du Caire SAE
19
Adly Street
Tel: (20-2)
3926915
Fax: (20-2)
3951713
·
National
Bank of
24,
Tel : (20-2) 3924175
Fax : (20-2) 3924143
PAYMENT HISTORY
No complaints regarding
subject’s payments have been reported.
GENERAL COMMENTS
Opinion on the
credit figure of US$ 100,000
Kahira Pharmaceuticals & Chemical Industries Co SAE is
well established in the Egyptian market with operations dating back 45 years.
The company specialises in the manufacture and export of human and veterinary drugs,
cosmetics, chemical products and pesticides.
During the course
of this investigation nothing detrimental was uncovered regarding subject’s
operating history or the manner in which payments are fulfilled. As such the
company is considered to be a fair trade risk and the above credit figure is
within subject’s financial means.
Maximum suggested
credit figure: US$ 800,000
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)